DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Boston Convention and Exhibition Center

2013年6月23日 (日) 午前 8:30 - 2013年6月27日 (木) 午後 12:45

415 Summer Street, , Boston, MA 02210 , USA

DIA 2013 49th Annual Meeting: Advancing Therapeutic Innovation and Regulatory Science

Enforcement Trends and Public Policy: Lessons Learned and Practices to Follow

Session Chair(s)

Barry  Berger, JD, MBA

Barry Berger, JD, MBA

Retired

Former Professor of Regulatory Affairs, Temple University, United States

In the context of recent compliance and enforcement trends, this forum will ask and answer such questions as: Should FDA and other government agencies place more of a priority on criminal enforcement? How has the Park doctrine and the Responsible Corporate Officer doctrine evolved, and is this good public policy? What is the significance of recent False Claims and Whistleblower lawsuits? What is the significance of the Foreign Corrupt Practices Act on our global industry? And, what can we learn from past government actions, and how should what we learn impact our future practices?

Learning Objective : Discuss if there is a need for FDA or other government agencies to play more of an enforcement role; Discuss if the Responsible Corporate Officer doctrine represents good public policy; Identify what other enforcement actions have been and are being taken by regulators that impact industry and the public; Discuss recent False Claims and Whistleblower actions; Discuss the significance of the Foreign Corrupt Practices Act.

Speaker(s)

Adolfo R. Garcia, JD

Panelist

Adolfo R. Garcia, JD

Brown Rudnick, United States

Partner

Susan G. Winkler

Panelist

Susan G. Winkler

US Attorney's Office, District of Massachusetts, United States

Assistant US Attorney

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。